SIREN : 529421778
PHARMACOS GROUP is a French company founded 15 years ago, specialized in the sector Activités des sociétés holding. Based in POLLIONNAY (69290), this company of category PME shows in 2024 a revenue of 278 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 277 900 € | 249 244 € | 234 875 € | 82 300 € | 361 643 € | 275 700 € | 321 999 € | 312 000 € | 312 000 € | 254 069 € |
| Net income | 164 231 € | -6 325 € | -91 294 € | -17 441 € | 58 603 € | 631 206 € | 2 077 764 € | 116 940 € | 126 735 € | 59 776 € |
| EBITDA | -52 861 € | -107 223 € | -167 695 € | -41 555 € | 8 084 € | -91 056 € | -42 773 € | -7 768 € | 30 965 € | 13 223 € |
| Net margin | 59.1% | -2.5% | -38.9% | -21.2% | 16.2% | 228.9% | 645.3% | 37.5% | 40.6% | 23.5% |
In 2024, PHARMACOS GROUP achieves revenue of 278 k€. Revenue is growing positively over 10 years (CAGR: +1.1%). Vs 2023, growth of +11% (249 k€ -> 278 k€). After deducting consumption (2 k€), gross margin stands at 276 k€, i.e. a rate of 99%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -53 k€, representing -19.0% of revenue. Positive scissor effect: EBITDA margin improves by +24.0 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 164 k€, i.e. 59.1% of revenue. This profit can be retained or distributed to shareholders.
277 900 €
275 789 €
-52 861 €
-110 745 €
164 231 €
-19.0%
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 90%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 27.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
10.704%
89.769%
27.623%
0.046
60.9%
In 2024, the debt ratio of PHARMACOS GROUP (10.70) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMACOS GROUP (89.8%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of PHARMACOS GROUP (0.05) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 555.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
555.154
-37.529
In 2024, the liquidity ratio of PHARMACOS GROUP (555.15) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of PHARMACOS GROUP (-37.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 270 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 35 days. The gap of 235 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 238 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 1330 days of revenue, i.e. 1.0 M€ to permanently finance. Over 2016-2024, WCR increased by +2764%, requiring additional financing.
1 026 376 €
270 j
35 j
238 j
1330 j
Based on 54 transactions of similar company sales
in 2024,
the value of PHARMACOS GROUP is estimated at
194 080 €
(range 122 244€ - 607 328€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMACOS GROUP with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of PHARMACOS GROUP in 2024 is 278 k€.
Yes, PHARMACOS GROUP generated a net profit of 164 k€ in 2024.
The headquarters of PHARMACOS GROUP is located in POLLIONNAY (69290), in the department Rhone.
The tax return of PHARMACOS GROUP is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMACOS GROUP operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.